The FDA told Fortune in a statement that it’s a pilot program which “advances the Commissioner’s goal of improving efficiency while fully maintaining FDA’s rigorous scientific standards and requirements.” The program intends to reward review staff “for efficiency and excellence,” but it won’t change review criteria, evidentiary thresholds, or quality safeguards.
Дональд ТрампПрезидент США
，更多细节参见体育直播
分析：伊朗政權架構仍在運作，未來幾天將顯示它是否能夠撐下去。同城约会对此有专业解读
优点： 无需 BatchNorm。